172 related articles for article (PubMed ID: 26992206)
1. Radiation dose escalation by simultaneous modulated accelerated radiotherapy combined with chemotherapy for esophageal cancer: a phase II study.
Chen J; Guo H; Zhai T; Chang D; Chen Z; Huang R; Zhang W; Lin K; Guo L; Zhou M; Li D; Li D; Chen C
Oncotarget; 2016 Apr; 7(16):22711-9. PubMed ID: 26992206
[TBL] [Abstract][Full Text] [Related]
2. Long-term results of concurrent chemoradiotherapy with daily-low-dose continuous infusion of 5-fluorouracil and cisplatin (LDFP) for Stage I-II esophageal carcinoma.
Kumabe A; Fukada J; Kota R; Koike N; Shiraishi Y; Seki S; Yoshida K; Kitagawa Y; Shigematsu N
Dis Esophagus; 2018 Apr; 31(4):. PubMed ID: 29228166
[TBL] [Abstract][Full Text] [Related]
3. Twice-daily radiotherapy as concurrent boost technique during two chemotherapy cycles in neoadjuvant chemoradiotherapy for resectable esophageal carcinoma: mature results of phase II study.
Choi N; Park SD; Lynch T; Wright C; Ancukiewicz M; Wain J; Donahue D; Mathisen D
Int J Radiat Oncol Biol Phys; 2004 Sep; 60(1):111-22. PubMed ID: 15337546
[TBL] [Abstract][Full Text] [Related]
4. High-dose versus standard-dose radiotherapy with concurrent chemotherapy in stages II-III esophageal cancer.
Suh YG; Lee IJ; Koom WS; Cha J; Lee JY; Kim SK; Lee CG
Jpn J Clin Oncol; 2014 Jun; 44(6):534-40. PubMed ID: 24771865
[TBL] [Abstract][Full Text] [Related]
5. Results of a Phase 1/2 Trial of Chemoradiotherapy With Simultaneous Integrated Boost of Radiotherapy Dose in Unresectable Locally Advanced Esophageal Cancer.
Chen D; Menon H; Verma V; Seyedin SN; Ajani JA; Hofstetter WL; Nguyen QN; Chang JY; Gomez DR; Amini A; Swisher SG; Blum MA; Younes AI; Barsoumian HB; Erasmus JJ; Lee JH; Bhutani MS; Hess KR; Minsky BD; Welsh JW
JAMA Oncol; 2019 Nov; 5(11):1597-1604. PubMed ID: 31529018
[TBL] [Abstract][Full Text] [Related]
6. Selective dose escalation of chemoradiotherapy for esophageal cancer: role of treatment intensification.
Seung SK; Smith JW; Molendyk J; Bader SB; Phillips M; Regan J; Louie J; Soo E; Seligman M; Ruzich J; Skokan L; Ross HJ
Semin Oncol; 2004 Dec; 31(6 Suppl 18):13-9. PubMed ID: 15726517
[TBL] [Abstract][Full Text] [Related]
7. [A Phase I/II Study of Chemotherapy Concurrent with Twice-daily Radiotherapy
Schedules by Intensity Modulated Radiation Therapy Using Simultaneous Integrated Boost for Limited-stage Small Cell Lung Cancer].
You J; Yu H; Song M; Shi C; Wang X; Zheng Y; Yu R; Shi A; Zhu G
Zhongguo Fei Ai Za Zhi; 2017 Jan; 20(1):28-34. PubMed ID: 28103970
[TBL] [Abstract][Full Text] [Related]
8. Definitive chemoradiation therapy with docetaxel, cisplatin, and 5-fluorouracil (DCF-R) in advanced esophageal cancer: a phase 2 trial (KDOG 0501-P2).
Higuchi K; Komori S; Tanabe S; Katada C; Azuma M; Ishiyama H; Sasaki T; Ishido K; Katada N; Hayakawa K; Koizumi W;
Int J Radiat Oncol Biol Phys; 2014 Jul; 89(4):872-9. PubMed ID: 24867539
[TBL] [Abstract][Full Text] [Related]
9. Toxicity, response rates and survival outcomes of induction cisplatin and irinotecan followed by concurrent cisplatin, irinotecan and radiotherapy for locally advanced esophageal cancer.
Watkins JM; Zauls AJ; Kearney PL; Shirai K; Ruppert BN; Harper JL; Sherman CA; Aguero EG; Reed CE; Sharma AK
Jpn J Clin Oncol; 2011 Mar; 41(3):334-42. PubMed ID: 21084436
[TBL] [Abstract][Full Text] [Related]
10. [Phase II clinical trial of concurrent chemoradiotherapy (cisplatin plus 5-fluorouracil) for esophageal cancer].
Lin Q; Gao XS; Qiao XY; Chen K; Wang YD; Zhou ZG
Ai Zheng; 2008 Oct; 27(10):1077-81. PubMed ID: 18851788
[TBL] [Abstract][Full Text] [Related]
11. Phase II study of use of a single cycle of induction chemotherapy and concurrent chemoradiotherapy containing capecitabine/cisplatin followed by surgery for patients with resectable esophageal squamous cell carcinoma: long-term follow-up data.
Koo DH; Park SI; Kim YH; Kim JH; Jung HY; Lee GH; Choi KD; Song HJ; Song HY; Shin JH; Cho KJ; Yoon DH; Kim SB
Cancer Chemother Pharmacol; 2012 Mar; 69(3):655-63. PubMed ID: 21968953
[TBL] [Abstract][Full Text] [Related]
12. Phase II study of concurrent chemoradiotherapy at the dose of 50.4 Gy with elective nodal irradiation for Stage II-III esophageal carcinoma.
Kato K; Nakajima TE; Ito Y; Katada C; Ishiyama H; Tokunaga SY; Tanaka M; Hironaka S; Hashimoto T; Ura T; Kodaira T; Yoshimura K
Jpn J Clin Oncol; 2013 Jun; 43(6):608-15. PubMed ID: 23585687
[TBL] [Abstract][Full Text] [Related]
13. Phase II study of cisplatin and 5-fluorouracil with concurrent radiotherapy in advanced squamous cell carcinoma of the esophagus: a Japan Esophageal Oncology Group (JEOG)/Japan Clinical Oncology Group trial (JCOG9516).
Ishida K; Ando N; Yamamoto S; Ide H; Shinoda M
Jpn J Clin Oncol; 2004 Oct; 34(10):615-9. PubMed ID: 15591460
[TBL] [Abstract][Full Text] [Related]
14. Long-term results of paclitaxel plus cisplatin with concurrent radiotherapy for loco-regional esophageal squamous cell carcinoma.
Zhu HT; Ai DS; Tang HR; Badakhshi H; Fan JH; Deng JY; Zhang JH; Chen Y; Zhang Z; Xia Y; Guo XM; Jiang GL; Zhao KL
World J Gastroenterol; 2017 Jan; 23(3):540-546. PubMed ID: 28210091
[TBL] [Abstract][Full Text] [Related]
15. Intensity-modulated radiation therapy with simultaneous integrated boost combined with concurrent chemotherapy for the treatment of anal cancer patients: 4-year results of a consecutive case series.
Franco P; Mistrangelo M; Arcadipane F; Munoz F; Sciacero P; Spadi R; Migliaccio F; Angelini V; Bombaci S; Rondi N; Numico G; Ragona R; Cassoni P; Morino M; Racca P; Ricardi U
Cancer Invest; 2015 Jul; 33(6):259-66. PubMed ID: 25950188
[TBL] [Abstract][Full Text] [Related]
16. Phase I/II study of docetaxel, cisplatin, and 5-fluorouracil combination chemoradiotherapy in patients with advanced esophageal cancer.
Miyazaki T; Sohda M; Tanaka N; Suzuki S; Ieta K; Sakai M; Sano A; Yokobori T; Inose T; Nakajima M; Fukuchi M; Ojima H; Kato H; Kuwano H
Cancer Chemother Pharmacol; 2015 Mar; 75(3):449-55. PubMed ID: 25544126
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of concurrent chemoradiotherapy as a palliative treatment in stage IVB esophageal cancer patients with dysphagia.
Ikeda E; Kojima T; Kaneko K; Minashi K; Onozawa M; Nihei K; Fuse N; Yano T; Yoshino T; Tahara M; Doi T; Ohtsu A
Jpn J Clin Oncol; 2011 Aug; 41(8):964-72. PubMed ID: 21742654
[TBL] [Abstract][Full Text] [Related]
18. A phase II trial of concurrent chemoradiotherapy with weekly paclitaxel and carboplatin in advanced oesophageal carcinoma.
Xia Y; Li YH; Chen Y; Liu Q; Zhang JH; Deng JY; Ai TS; Zhu HT; Badakhshi H; Zhao KL
Int J Clin Oncol; 2018 Jun; 23(3):458-465. PubMed ID: 29435872
[TBL] [Abstract][Full Text] [Related]
19. High-dose definitive concomitant chemoradiotherapy in non-metastatic locally advanced esophageal cancer: toxicity and outcome.
Hurmuzlu M; Monge OR; Smaaland R; Viste A
Dis Esophagus; 2010 Apr; 23(3):244-52. PubMed ID: 19664075
[TBL] [Abstract][Full Text] [Related]
20. Elective lymph node irradiation late course accelerated hyper-fractionated radiotherapy plus concurrent cisplatin-based chemotherapy for esophageal squamous cell carcinoma: a phase II study.
Wang D; Yang J; Zhu J; Li B; Zhai L; Sun M; Gong H; Zhou T; Wei Y; Huang W; Wang Z; Li H; Zhang Z
Radiat Oncol; 2013 May; 8():108. PubMed ID: 23638721
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
